Skip to main content
Top
Published in: BMC Infectious Diseases 1/2016

Open Access 01-12-2015 | Research article

Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study

Authors: Gustavo E. Velásquez, J. Peter Cegielski, Megan B. Murray, Martin J. A. Yagui, Luis L. Asencios, Jaime N. Bayona, César A. Bonilla, Hector O. Jave, Gloria Yale, Carmen Z. Suárez, Eduardo Sanchez, Christian Rojas, Sidney S. Atwood, Carmen C. Contreras, Janeth Santa Cruz, Sonya S. Shin

Published in: BMC Infectious Diseases | Issue 1/2016

Login to get access

Abstract

Background

Human immunodeficiency virus (HIV)-associated tuberculosis deaths have decreased worldwide over the past decade. We sought to evaluate the effect of HIV status on tuberculosis mortality among patients undergoing treatment for tuberculosis in Lima, Peru, a low HIV prevalence setting.

Methods

We conducted a prospective cohort study of patients treated for tuberculosis between 2005 and 2008 in two adjacent health regions in Lima, Peru (Lima Ciudad and Lima Este). We constructed a multivariate Cox proportional hazards model to evaluate the effect of HIV status on mortality during tuberculosis treatment.

Results

Of 1701 participants treated for tuberculosis, 136 (8.0 %) died during tuberculosis treatment. HIV-positive patients constituted 11.0 % of the cohort and contributed to 34.6 % of all deaths. HIV-positive patients were significantly more likely to die (25.1 vs. 5.9 %, P < 0.001) and less likely to be cured (28.3 vs. 39.4 %, P = 0.003). On multivariate analysis, positive HIV status (hazard ratio [HR] = 6.06; 95 % confidence interval [CI], 3.96–9.27), unemployment (HR = 2.24; 95 % CI, 1.55–3.25), and sputum acid-fast bacilli smear positivity (HR = 1.91; 95 % CI, 1.10–3.31) were significantly associated with a higher hazard of death.

Conclusions

We demonstrate that positive HIV status was a strong predictor of mortality among patients treated for tuberculosis in the early years after Peru started providing free antiretroviral therapy. As HIV diagnosis and antiretroviral therapy provision are more widely implemented for tuberculosis patients in Peru, future operational research should document the changing profile of HIV-associated tuberculosis mortality.
Literature
1.
go back to reference World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization; 2014. p. 1–171. World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization; 2014. p. 1–171.
2.
go back to reference World Health Organization. Interim policy on collaborative TB/HIV activities. Geneva: World Health Organization; 2004. p. 1–20. World Health Organization. Interim policy on collaborative TB/HIV activities. Geneva: World Health Organization; 2004. p. 1–20.
3.
go back to reference World Health Organization. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva: World Health Organization; 2012. p. 1–36. World Health Organization. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva: World Health Organization; 2012. p. 1–36.
4.
go back to reference Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492–501.PubMedCentralCrossRefPubMed Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492–501.PubMedCentralCrossRefPubMed
5.
go back to reference Blanc F-X, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471–81.CrossRefPubMed Blanc F-X, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471–81.CrossRefPubMed
6.
go back to reference Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482–91.PubMedCentralCrossRefPubMed Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482–91.PubMedCentralCrossRefPubMed
7.
go back to reference Török ME, Yen NTB, Chau TTH, Mai NTH, Phu NH, Mai PP, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis. 2011;52:1374–83.PubMedCentralCrossRefPubMed Török ME, Yen NTB, Chau TTH, Mai NTH, Phu NH, Mai PP, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis. 2011;52:1374–83.PubMedCentralCrossRefPubMed
8.
go back to reference Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Likanonsakul S, Suwanvattana P, et al. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr. 2012;60:377–83.CrossRefPubMed Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Likanonsakul S, Suwanvattana P, et al. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr. 2012;60:377–83.CrossRefPubMed
9.
go back to reference Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, Borand L, et al. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. Clin Infect Dis. 2014;59:435–45.PubMedCentralCrossRefPubMed Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, Borand L, et al. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. Clin Infect Dis. 2014;59:435–45.PubMedCentralCrossRefPubMed
11.
go back to reference World Health Organization. Global tuberculosis report 2013. Geneva: World Health Organization; 2013. p. 1–306. World Health Organization. Global tuberculosis report 2013. Geneva: World Health Organization; 2013. p. 1–306.
12.
go back to reference Shin SS, Yagui MJA, Asencios L, Yale G, Suárez CZ, Quispe N, et al. Scale-up of multidrug-resistant tuberculosis laboratory services, Peru. Emerg Infect Dis. 2008;14:701–8.PubMedCentralCrossRefPubMed Shin SS, Yagui MJA, Asencios L, Yale G, Suárez CZ, Quispe N, et al. Scale-up of multidrug-resistant tuberculosis laboratory services, Peru. Emerg Infect Dis. 2008;14:701–8.PubMedCentralCrossRefPubMed
13.
go back to reference Norma Técnica De Salud Para El Control De La Tuberculosis. Lima: Estrategia Sanitaria Nacional para la Prevención y Control de la Tuberculosis, Dirección General de Salud de las Personas, Ministerio de Salud; 2006. Norma Técnica De Salud Para El Control De La Tuberculosis. Lima: Estrategia Sanitaria Nacional para la Prevención y Control de la Tuberculosis, Dirección General de Salud de las Personas, Ministerio de Salud; 2006.
14.
go back to reference Velásquez GE, Yagui MJA, Cegielski JP, Asencios L, Bayona J, Bonilla C, et al. Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005–2008. Emerg Infect Dis. 2011;17:432–40.PubMedCentralCrossRefPubMed Velásquez GE, Yagui MJA, Cegielski JP, Asencios L, Bayona J, Bonilla C, et al. Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005–2008. Emerg Infect Dis. 2011;17:432–40.PubMedCentralCrossRefPubMed
15.
go back to reference Shin SS, Asencios L, Yagui MJA, Yale G, Suárez CZ, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2012;16:1538–43.CrossRefPubMed Shin SS, Asencios L, Yagui MJA, Yale G, Suárez CZ, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2012;16:1538–43.CrossRefPubMed
16.
go back to reference Asencios L, Yale G, Yagui MJA, Quispe N, Taylor A, Blaya JA, et al. Programmatic implementation of rapid DST for Mycobacterium tuberculosis in Peru. Int J Tuberc Lung Dis. 2008;12:743–9.PubMed Asencios L, Yale G, Yagui MJA, Quispe N, Taylor A, Blaya JA, et al. Programmatic implementation of rapid DST for Mycobacterium tuberculosis in Peru. Int J Tuberc Lung Dis. 2008;12:743–9.PubMed
17.
go back to reference Roberts GD, Goodman NL, Heifets L, Larsh HW, Lindner TH, McClatchy JK, et al. Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens. J Clin Microbiol. 1983;18:689–96.PubMedCentralPubMed Roberts GD, Goodman NL, Heifets L, Larsh HW, Lindner TH, McClatchy JK, et al. Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens. J Clin Microbiol. 1983;18:689–96.PubMedCentralPubMed
18.
go back to reference Asencios L, Sloutsky A, Stowel M. Método De Nitrato-Reductasa (GRIESS) Para La Detección Rápida De La Susceptibilidad a Isoniacida Y Rifampicina. Lima: Ministerio de Salud, Instituto Nacional de Salud; 2012. Asencios L, Sloutsky A, Stowel M. Método De Nitrato-Reductasa (GRIESS) Para La Detección Rápida De La Susceptibilidad a Isoniacida Y Rifampicina. Lima: Ministerio de Salud, Instituto Nacional de Salud; 2012.
19.
go back to reference World Health Organization. Scaling Up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 revision. Geneva: World Health Organization; 2004. p. 1–68. World Health Organization. Scaling Up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 revision. Geneva: World Health Organization; 2004. p. 1–68.
20.
go back to reference Blaya JA, Shin SS, Yagui MJA, Yale G, Suárez CZ, Asencios L, et al. A web-based laboratory information system to improve quality of care of tuberculosis patients in Peru: functional requirements, implementation and usage statistics. BMC Med Inform Decis Mak. 2007;7:33.PubMedCentralCrossRefPubMed Blaya JA, Shin SS, Yagui MJA, Yale G, Suárez CZ, Asencios L, et al. A web-based laboratory information system to improve quality of care of tuberculosis patients in Peru: functional requirements, implementation and usage statistics. BMC Med Inform Decis Mak. 2007;7:33.PubMedCentralCrossRefPubMed
21.
go back to reference Mitnick CD, Bayona JJ, Palacios EE, Shin SS, Furin JJ, Alcántara FF, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348:119–28.CrossRefPubMed Mitnick CD, Bayona JJ, Palacios EE, Shin SS, Furin JJ, Alcántara FF, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348:119–28.CrossRefPubMed
22.
go back to reference Mukherjee JS, Rich ML, Socci AR, Joseph JK, Virú FA, Shin SS, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004;363:474–81.CrossRefPubMed Mukherjee JS, Rich ML, Socci AR, Joseph JK, Virú FA, Shin SS, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004;363:474–81.CrossRefPubMed
23.
go back to reference World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. Geneva: World Health Organization; 2010. p. 1–160. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. Geneva: World Health Organization; 2010. p. 1–160.
24.
go back to reference Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640–5.PubMed Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640–5.PubMed
25.
go back to reference Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis. 2006;10:402–8.PubMed Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis. 2006;10:402–8.PubMed
26.
go back to reference Kawai V, Soto G, Gilman RH, Bautista CT, Caviedes L, Huaroto L, et al. Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg. 2006;75:1027–33.PubMedCentralPubMed Kawai V, Soto G, Gilman RH, Bautista CT, Caviedes L, Huaroto L, et al. Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg. 2006;75:1027–33.PubMedCentralPubMed
27.
go back to reference Bernabé-Ortiz A. Factors associated with survival of patients with tuberculosis in Lima, Peru. Rev Chilena Infectol. 2008;25:104–7.CrossRefPubMed Bernabé-Ortiz A. Factors associated with survival of patients with tuberculosis in Lima, Peru. Rev Chilena Infectol. 2008;25:104–7.CrossRefPubMed
28.
go back to reference Duarte EC, Bierrenbach AL, da Silva JB, Tauil PL, de Fátima Duarte E. Factors associated with deaths among pulmonary tuberculosis patients: a case–control study with secondary data. J Epidemiol Community Health. 2009;63:233–8.CrossRefPubMed Duarte EC, Bierrenbach AL, da Silva JB, Tauil PL, de Fátima Duarte E. Factors associated with deaths among pulmonary tuberculosis patients: a case–control study with secondary data. J Epidemiol Community Health. 2009;63:233–8.CrossRefPubMed
29.
go back to reference Getahun B, Ameni G, Biadgilign S, Medhin G. Mortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia. BMC Infect Dis. 2011;11:127.PubMedCentralCrossRefPubMed Getahun B, Ameni G, Biadgilign S, Medhin G. Mortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia. BMC Infect Dis. 2011;11:127.PubMedCentralCrossRefPubMed
30.
go back to reference Kliiman K, Altraja A. Predictors and mortality associated with treatment default in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2010;14:454–63.PubMed Kliiman K, Altraja A. Predictors and mortality associated with treatment default in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2010;14:454–63.PubMed
31.
go back to reference Lefebvre N, Falzon D. Risk factors for death among tuberculosis cases: analysis of European surveillance data. Eur Respir J. 2008;31:1256–60.CrossRefPubMed Lefebvre N, Falzon D. Risk factors for death among tuberculosis cases: analysis of European surveillance data. Eur Respir J. 2008;31:1256–60.CrossRefPubMed
32.
go back to reference Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra MC, Danilovitz M, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb). 2012;92:397–403.CrossRef Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra MC, Danilovitz M, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb). 2012;92:397–403.CrossRef
33.
go back to reference Palacios E, Franke M, Muñoz M, Hurtado R, Dallman R, Chalco K, et al. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis. 2012;16:348–54.CrossRefPubMed Palacios E, Franke M, Muñoz M, Hurtado R, Dallman R, Chalco K, et al. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis. 2012;16:348–54.CrossRefPubMed
34.
go back to reference Périssé ARS, Smeaton L, Chen Y, La Rosa A, Walawander A, Nair A, et al. Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease. PLoS ONE. 2013;8, e83643.PubMedCentralCrossRefPubMed Périssé ARS, Smeaton L, Chen Y, La Rosa A, Walawander A, Nair A, et al. Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease. PLoS ONE. 2013;8, e83643.PubMedCentralCrossRefPubMed
35.
go back to reference Chung-Delgado K, Guillen-Bravo S, Revilla-Montag A, Bernabé-Ortiz A. Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. PLoS ONE. 2015;10, e0119332.PubMedCentralCrossRefPubMed Chung-Delgado K, Guillen-Bravo S, Revilla-Montag A, Bernabé-Ortiz A. Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. PLoS ONE. 2015;10, e0119332.PubMedCentralCrossRefPubMed
36.
go back to reference Sebastian JL, Bonilla C, Lecca LW, Contreras C, Muñoz M, Palacios E, et al. Community-based liaisons to improve referral and access to HIV treatment for TB co-infected patients in Peru. Mexico: Presented at the XVII International AIDS Conference; 2008. Sebastian JL, Bonilla C, Lecca LW, Contreras C, Muñoz M, Palacios E, et al. Community-based liaisons to improve referral and access to HIV treatment for TB co-infected patients in Peru. Mexico: Presented at the XVII International AIDS Conference; 2008.
Metadata
Title
Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study
Authors
Gustavo E. Velásquez
J. Peter Cegielski
Megan B. Murray
Martin J. A. Yagui
Luis L. Asencios
Jaime N. Bayona
César A. Bonilla
Hector O. Jave
Gloria Yale
Carmen Z. Suárez
Eduardo Sanchez
Christian Rojas
Sidney S. Atwood
Carmen C. Contreras
Janeth Santa Cruz
Sonya S. Shin
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-1375-8

Other articles of this Issue 1/2016

BMC Infectious Diseases 1/2016 Go to the issue